Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems

An ongoing need for new cancer therapeutics exists, especially ones that specifically home and target triple-negative breast cancer. Because triple-negative breast cancer express low or are devoid of estrogen, progesterone, or Her2/Neu receptors, another target must be used for advanced drug deliver...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Samir V., Nima, Zeid A., Vang, Kieng B., Kannarpady, Ganesh, Nedosekin, Dmitry A., Zharov, Vladimir P., Griffin, Robert J., Biris, Alexandru S., Dings, Ruud P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871908/
https://www.ncbi.nlm.nih.gov/pubmed/29872709
http://dx.doi.org/10.1038/s41698-017-0030-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871908/
https://www.ncbi.nlm.nih.gov/pubmed/29872709
http://dx.doi.org/10.1038/s41698-017-0030-1

Ejemplares similares